FrancophonIA/ELRC3.0 huggingface dataset:
English: Mean percent changes from baseline for ertugliflozin 5 mg and 15 mg versus placebo, respectively, were LDL-C 5.8% and 8.4% versus 3.2%; total cholesterol 2.8% and 5.7% versus 1.1%; however, HDL-C 6.2% and 7.6% versus 1.9%.
Croatian: Srednja vrijednost postotne promjene početne vrijednosti LDL-kolesterola iznosila je 5,8% uz ertugliflozin u dozi od 5 mg odnosno 8,4% uz ertugliflozin u dozi od 15 mg naspram 3,2% uz placebo, dok je za ukupni kolesterol iznosila 2,8% uz ertugliflozin u dozi od 5 mg odnosno 5,7% uz ertugliflozin u dozi od 15 mg naspram 1,1% uz placebo; međutim, za HDL-kolesterol iznosila je 6,2% uz ertugliflozin u dozi od 5mg odnosno 7,6% uz ertugliflozin u dozi od 15 mg naspram 1,9% uz placebo.
English: Segluromet 2.5 mg/850 mg film-coated tablets Segluromet 2.5 mg/1,000 mg film-coated tablets Segluromet 7.5 mg/850 mg film-coated tablets Segluromet 7.5 mg/1,000 mg film-coated tablets
Croatian: Segluromet 2,5 mg/850 mg filmom obložene tablete Segluromet 2,5 mg/1000 mg filmom obložene tablete Segluromet 7,5 mg/850 mg filmom obložene tablete Segluromet 7,5 mg/1000 mg filmom obložene tablete
English: A total of 1,326 patients with type 2 diabetes inadequately controlled on metformin monotherapy participated in a randomised, double-blind, multi-centre, 52-week, active comparator-controlled study to evaluate the efficacy and safety of ertugliflozin in combination with metformin.
Croatian: Ukupno je 1326 bolesnika s dijabetesom tipa 2 i nedovoljno dobrom regulacijom glikemije uz monoterapiju metforminom sudjelovalo u 52-tjednom randomiziranom, dvostruko slijepom, multicentričnom, aktivnim usporednim lijekom kontroliranom ispitivanju provedenom radi ocjenjivanja djelotvornosti i sigurnosti ertugliflozina u kombinaciji s metforminom.
English: Patients were randomised to ertugliflozin 5 mg, ertugliflozin 15 mg, or placebo administered once daily in addition to continuation of background metformin and sitagliptin therapy (see Table 4).
Croatian: Bolesnici su bili randomizirani za primanje ertugliflozina u dozi od 5 mg, ertugliflozina u dozi od 15 mg ili placeba jedanput na dan kao dodatka kontinuiranoj osnovnoj terapiji metforminom i sitagliptinom (vidjeti Tablicu 4).
English: The proportion of subjects having at least 1 increase in haemoglobin > 2.0 g/dL was higher in the ertugliflozin 5 mg and 15 mg groups (4.7% and 4.1%, respectively) compared to the placebo group (0.6%).
Croatian: Udio ispitanika koji su doživjeli najmanje 1 povećanje vrijednosti hemoglobina za ˃ 2,0 g/dl bio je veći u skupinama liječenima ertugliflozinom u dozi od 5 mg odnosno 15 mg (4,7% odnosno 4,1%) nego u onoj koja je primala placebo à
English: Factorial study with ertugliflozin and sitagliptin as add-on combination therapy with metformin A total of 1,233 patients with type 2 diabetes participated in a randomised, double-blind, multi-centre, 26-week, active-controlled study to evaluate the efficacy and safety of ertugliflozin 5 mg or 15 mg in combination with sitagliptin 100 mg compared to the individual components.
Croatian: Ukupno su 1233 bolesnika s dijabetesom tipa 2 sudjelovala u 26-tjednom randomiziranom, dvostruko slijepom, multicentričnom, aktivnim lijekom kontroliranom ispitivanju provedenom radi ocjenjivanja djelotvornosti i sigurnosti ertugliflozina u dozi od 5 mg ili 15 mg u kombinaciji sa sitagliptinom u dozi od 100 mg u odnosu na pojedinačne sastavnice.
English: Your blood sugar levels may increase if you stop the medicine.
Croatian: Ako prestanete uzimati lijek, mogu Vam se povisiti razine šećera u krvi.
English: Coadministration of metformin with
Croatian: Istodobna primjena metformina sa:
English: Following single-dose oral administration of 5 mg and 15 mg of ertugliflozin, peak plasma concentrations (median Tmax) of ertugliflozin occur at 1 hour post-dose under fasted conditions.
Croatian: Vršne koncentracije ertugliflozina u plazmi (medijan Tmax) nakon primjene jednokratne peroralne doze od 5 mg i 15 mg nastupaju 1 sat nakon primjene natašte.
English: Patients were randomised to ertugliflozin 5 mg, ertugliflozin 15 mg, or placebo administered once daily in addition to continuation of background metformin therapy (see Table 2).
Croatian: Bolesnici su bili randomizirani za primanje ertugliflozina u dozi od 5 mg, ertugliflozina u dozi od 15 mg ili placeba jedanput na dan kao dodatka kontinuiranoj osnovnoj terapiji metforminom (vidjeti Tablicu 2).
English: Vulvovaginal mycotic infection and other female genital mycotic infections*
Croatian: Infekcije i infestacije vrlo često često nepoznato vulvovaginalna gljivična infekcija i druge genitalne gljivične infekcije u žena*
English: Median percent changes from baseline for ertugliflozin 5 mg and 15 mg versus placebo, respectively, were triglycerides -3.9% and -1.7% versus 4.5%.
Croatian: Medijan postotne promjene početne vrijednosti triglicerida iznosio je -3,9% uz ertugliflozin u dozi od 5 mg odnosno -1,7% uz ertugliflozin u dozi od 15 mg naspram 4,5% uz placebo.
English: Fertility of male or female rats was unaffected by metformin when administered at doses as high as 600 mg/kg/day, which is approximately three times the maximum recommended human daily dose based on body surface area comparisons.
Croatian: Metformin primijenjen u dozama do čak 600 mg/kg na dan, što je približno tri puta veća doza od maksimalne preporučene dnevne doze za ljude, na temelju usporedbi tjelesne površine, nije utjecao na plodnost mužjaka ni ženki štakora.
English: • Segluromet 7.5 mg/1,000 mg film-coated tablets (tablets) are red, 19.1 x 10.6 mm oval, film-coated tablets debossed with “7.5/1000” on one side and plain on the other side.
Croatian: • Segluromet 7,5 mg/1000 mg filmom obložene tablete (tablete) su crvene, ovalne, filmom obložene tablete dimenzija 19,1 x 10,6 mm, s utisnutom oznakom „7.5/1000“ na jednoj strani i bez oznaka na drugoj strani.
English: • Segluromet 2.5 mg/1,000 mg film-coated tablets (tablets) are pink, 19.1 x 10.6 mm oval, film-coated tablets debossed with “2.5/1000” on one side and plain on the other side.
Croatian: • Segluromet 2,5 mg/1000 mg filmom obložene tablete (tablete) su ružičaste, ovalne, filmom obložene tablete dimenzija 19,1 x 10,6 mm, s utisnutom oznakom „2.5/1000“ na jednoj strani i bez oznaka na drugoj strani.
English: • Segluromet 2.5 mg/850 mg film-coated tablets (tablets) are beige, 18 x 10 mm oval, film-coated tablets debossed with “2.5/850” on one side and plain on the other side.
Croatian: • Segluromet 2,5 mg/850 mg filmom obložene tablete (tablete) su bež, ovalne, filmom obložene tablete dimenzija 18 x 10 mm, s utisnutom oznakom „2.5/850“ na jednoj strani i bez oznaka na drugoj strani.
English: Factors that may increase the risk of lactic acidosis (see section 4.4) should be reviewed before considering initiation of metformin in patients with GFR < 60 ml/min.
Croatian: Prije nego što se razmotri uvođenje metformina u bolesnika kojima je GFR < 60 ml/min treba procijeniti čimbenike koji bi mogli povećati rizik od laktacidoze (vidjeti dio 4.4).
English: Baseline (mean)
Croatian: „kreatinina“)
English: There were no ertugliflozin-related neoplastic findings at doses up to 40 mg/kg/day (approximately 41 times human unbound exposure at the MRHD of 15 mg/day based on AUC).
Croatian: Pri dozama do 40 mg/kg na dan (razina izloženosti približno 41 puta veća od izloženosti nevezanom spoju u ljudi pri maksimalnoj preporučenoj dozi za ljude od 15 mg na dan, utvrđenoj na temelju AUC-a) nisu utvrđeni neoplastični nalazi povezani s ertugliflozinom.
English: Adverse reaction with metformin.
Croatian: Nuspojava uz metformin.
English: Ertugliflozin as add-on combination therapy with metformin A total of 621 patients with type 2 diabetes inadequately controlled on metformin monotherapy (≥ 1,500 mg/day) participated in a randomised, double-blind, multi-centre, 26-week, placebocontrolled study to evaluate the efficacy and safety of ertugliflozin in combination with metformin.
Croatian: Ukupno je 621 bolesnik s dijabetesom tipa 2 i nedovoljno dobrom regulacijom glikemije uz monoterapiju metforminom (≥ 1500 mg na dan) sudjelovao u 26-tjednom randomiziranom, dvostruko slijepom, multicentričnom, placebom kontroliranom ispitivanju provedenom radi ocjenjivanja djelotvornosti i sigurnosti ertugliflozina u kombinaciji s metforminom.
English: This may occur regardless of blood glucose level.
Croatian: Ovi se znakovi mogu javiti neovisno o razini šećera u krvi.
English: INTERMEDIATE CARTON WITHOUT BLUE BOX - MULTIPACKS - SEGLUROMET 7.5 mg/850 mg
Croatian: MEĐUPAKIRANJE BEZ PLAVOG OKVIRA - VIŠESTRUKA PAKIRANJASEGLUROMET 7,5 mg/850 mg
English: • Segluromet 7.5 mg/850 mg film-coated tablets (tablets) are dark brown, 18 x 10 mm oval, film-coated tablets debossed with “7.5/850” on one side and plain on the other side.
Croatian: • Segluromet 7,5 mg/850 mg filmom obložene tablete (tablete) su tamnosmeđe, ovalne, filmom obložene tablete dimenzija 18 x 10 mm, s utisnutom oznakom „7.5/850“ na jednoj strani i bez oznaka na drugoj strani.
English: Segluromet 7.5 mg/1,000 mg film-coated tablets EU/1/18/1265/022
Croatian: Segluromet 7,5 mg/1000 mg filmom obložene tablete EU/1/18/1265/022
English: BLISTER FOR SEGLUROMET 7.5 mg/1000 mg
Croatian: BLISTER ZA SEGLUROMET 7,5 mg/1000 mg
English: Medicinal products that can acutely impair renal function (such as antihypertensives, diuretics and non-steroidal anti-inflammatory drugs [NSAIDs]) should be initiated with caution in metformintreated patients.
Croatian: U bolesnika liječenih metforminom potreban je oprez kada se započinje s primjenom lijekova koji mogu akutno narušiti funkciju bubrega (kao što su antihipertenzivi, diuretici i nesteroidni protuupalni lijekovi [NSAIL]).
English: BLISTER FOR SEGLUROMET 2.5 mg/1000 mg
Croatian: BLISTER ZA SEGLUROMET 2,5 mg/1000 mg
English: INTERMEDIATE CARTON WITHOUT BLUE BOX - MULTIPACKS - SEGLUROMET 2.5 mg/850 mg
Croatian: MEĐUPAKIRANJE BEZ PLAVOG OKVIRA - VIŠESTRUKA PAKIRANJASEGLUROMET 2,5 mg/850 mg
English: BLISTER FOR SEGLUROMET 2.5 mg/850 mg
Croatian: BLISTER ZA SEGLUROMET 2,5 mg/850 mg
English: o Each Segluromet 2.5 mg/850 mg film-coated tablet contains 2.5 mg ertugliflozin (as ertugliflozin L-pyroglutamic acid) and 850 mg of metformin hydrochloride.
Croatian: o Jedna Segluromet 2,5 mg/850 mg filmom obložena tableta sadrži 2,5 mg ertugliflozina (u obliku ertugliflozin-L-piroglutamatne kiseline) i 850 mg metforminklorida.
English: Segluromet 2.5 mg/850 mg film-coated tablets EU/1/18/1265/001
Croatian: Segluromet 2,5 mg/850 mg filmom obložene tablete EU/1/18/1265/001
English: INTERMEDIATE CARTON WITHOUT BLUE BOX - MULTIPACKS - SEGLUROMET 7.5 mg/1000 mg
Croatian: MEĐUPAKIRANJE BEZ PLAVOG OKVIRA - VIŠESTRUKA PAKIRANJASEGLUROMET 7,5 mg/1000 mg
English: Therefore, a lower dose of insulin or an insulin secretagogue may be required to reduce the risk of hypoglycaemia when used in combination with Segluromet (see sections 4.2, 4.4, and 4.8).
Croatian: Stoga će kod primjene u kombinaciji s lijekom Segluromet možda biti potrebna manja doza inzulina ili inzulinskog sekretagoga kako bi se smanjio rizik od hipoglikemije (vidjeti dijelove 4.2, 4.4 i 4.8).
English: Each tablet contains 2.5 mg of ertugliflozin (as ertugliflozin L-pyroglutamic acid) and 1000 mg of metformin hydrochloride.
Croatian: Jedna tableta sadrži 2,5 mg ertugliflozina (u obliku ertugliflozin-L-piroglutamatne kiseline) i 1000 mg metforminklorida.
English: BLISTER FOR SEGLUROMET 7.5 mg/850 mg
Croatian: BLISTER ZA SEGLUROMET 7,5 mg/850 mg
English: Segluromet 7.5 mg/850 mg film-coated tablets EU/1/18/1265/015
Croatian: Segluromet 7,5 mg/850 mg filmom obložene tablete EU/1/18/1265/015
English: Segluromet 2.5 mg/1,000 mg film-coated tablets EU/1/18/1265/008
Croatian: Segluromet 2,5 mg/1000 mg filmom obložene tablete EU/1/18/1265/008
English: INTERMEDIATE CARTON WITHOUT BLUE BOX - MULTIPACKS - SEGLUROMET 2.5 mg/1000 mg
Croatian: MEĐUPAKIRANJE BEZ PLAVOG OKVIRA - VIŠESTRUKA PAKIRANJASEGLUROMET 2,5 mg/1000 mg
English: o Each Segluromet 7.5 mg/850 mg film-coated tablet contains 7.5 mg ertugliflozin (as ertugliflozin L-pyroglutamic acid) and 850 mg of metformin hydrochloride.
Croatian: o Jedna Segluromet 7,5 mg/850 mg filmom obložena tableta sadrži 7,5 mg ertugliflozina (u obliku ertugliflozin-L-piroglutamatne kiseline) i 850 mg metforminklorida.
English: Each tablet contains 7.5 mg of ertugliflozin (as ertugliflozin L-pyroglutamic acid) and 1000 mg of metformin hydrochloride.
Croatian: Jedna tableta sadrži 7,5 mg ertugliflozina (u obliku ertugliflozin-L-piroglutamatne kiseline) i 1000 mg metforminklorida.
English: Therefore, a lower dose of insulin or insulin secretagogue may be required to minimise the risk of hypoglycaemia when used in combination with Segluromet (see sections 4.2 and 4.5).
Croatian: Stoga će kod primjene u kombinaciji s lijekom Segluromet možda biti potrebna manja doza inzulina ili inzulinskog sekretagoga kako bi se smanjio rizik od hipoglikemije (vidjeti dijelove 4.2 i 4.5).
English: Do not take Segluromet if any of the above apply to you.
Croatian: Nemojte uzimati Segluromet ako dojite.
English: , BUN
Croatian: Česte
English: Segluromet 7.5 mg/850 mg tablets ertugliflozin/metformin hydrochloride
Croatian: Segluromet 7,5 mg/850 mg tablete ertugliflozin/metforminklorid
English: Dose-dependent increases in the amount of glucose excreted in urine were observed in healthy subjects and in patients with type 2 diabetes mellitus following single- and multiple-dose administration of ertugliflozin.
Croatian: U zdravih ispitanika i bolesnika s dijabetes mellitusom tipa 2 nakon primjene jedne i višestrukih doza ertugliflozina primijećeno je o dozi ovisno povećanje količine glukoze izlučene u mokraću.
English: Change from baseline (LS mean Difference from placebo (LS mean
Croatian: Razlika u odnosu na placebo (srednja vrijednost prema metodi najmanjih kvadrata
English: There was, however, an increased incidence of benign stromal uterine polyps in female rats treated with 900 mg/kg/day.
Croatian: Međutim, u ženki štakora koje su primale dozu od 900 mg/kg na dan zabilježena je povišena incidencija dobroćudnih stromalnih polipa uterusa.
English: Segluromet 2.5 mg/850 mg tablets ertugliflozin/metformin hydrochloride
Croatian: Segluromet 2,5 mg/850 mg tablete ertugliflozin/metforminklorid
English: Segluromet 7.5 mg/1000 mg tablets ertugliflozin/metformin hydrochloride
Croatian: Segluromet 7,5 mg/1000 mg tablete ertugliflozin/metforminklorid
English: Tel: + 421 (2) 58282010 dpoc_czechslovak@merck.com
Croatian: Slovenská republika Merck Sharp & Dohme, s.r.o. Tel: + 421 (2) 58282010 dpoc_czechslovak@merck.com
English: o Each Segluromet 7.5 mg/1,000 mg film-coated tablet contains 7.5 mg ertugliflozin (as ertugliflozin L-pyroglutamic acid) and 1,000 mg of metformin hydrochloride.
Croatian: o Jedna Segluromet 7,5 mg/1000 mg filmom obložena tableta sadrži 7,5 mg ertugliflozina (u obliku ertugliflozin-L-piroglutamatne kiseline) i 1000 mg metforminklorida.
English: Segluromet 7.5 mg/1,000 mg film-coated tablets Each tablet contains 7.5 mg ertugliflozin (as ertugliflozin L-pyroglutamic acid) and 1,000 mg metformin hydrochloride.
Croatian: Segluromet 7,5 mg/1000 mg filmom obložene tablete Jedna tableta sadrži 7,5 mg ertugliflozina (u obliku ertugliflozin-L-piroglutamatne kiseline) i 1000 mg metforminklorida.
English: Hepatobiliary disorders Very rare
Croatian: Poremećaji metabolizma i prehrane često rijetko vrlo rijetko hipoglikemija*
English: Segluromet 2.5 mg/1000 mg tablets ertugliflozin/metformin hydrochloride
Croatian: Segluromet 2,5 mg/1000 mg tablete ertugliflozin/metforminklorid
English: Nervous system disorders Common
Croatian: Poremećaji živčanog sustava često poremećaj osjeta okusa
English: 0.5% for ertugliflozin 5 mg, ertugliflozin 15 mg, and the comparator group and for subjects with eGFR 45 to < 60 mL/min/1.73 m2, the incidence was 6.4%, 3.7%, and 0% respectively.
Croatian: Incidencija u skupini liječenoj ertugliflozinom u dozi od 5 mg iznosila je 5,1%, u skupini liječenoj ertugliflozinom u dozi od 15 mg iznosila je 2,6% i 0,5% u skupini liječenoj usporednim lijekom, među ispitanicima kojima je eGFR bio < 60 ml/min/1,73 m2, dok je među onima kojima je eGFR bio između
English: o Each Segluromet 2.5 mg/1,000 mg film-coated tablet contains 2.5 mg ertugliflozin (as ertugliflozin L-pyroglutamic acid) and 1,000 mg of metformin hydrochloride.
Croatian: o Jedna Segluromet 2,5 mg/1000 mg filmom obložena tableta sadrži 2,5 mg ertugliflozina (u obliku ertugliflozin-L-piroglutamatne kiseline) i 1000 mg metforminklorida.
English: Segluromet 2.5 mg/1,000 mg film-coated tablets Each tablet contains 2.5 mg ertugliflozin (as ertugliflozin L-pyroglutamic acid) and 1,000 mg of metformin hydrochloride.
Croatian: Segluromet 2,5 mg/1000 mg filmom obložene tablete Jedna tableta sadrži 2,5 mg ertugliflozina (u obliku ertugliflozin-L-piroglutamatne kiseline) i 1000 mg metforminklorida.
English: Segluromet 7.5 mg/1000 mg film-coated tablets ertugliflozin/metformin hydrochloride
Croatian: Segluromet 7,5 mg/1000 mg filmom obložene tablete ertugliflozin/metforminklorid
English: Change from baseline (LS mean Difference from glimepiride (LS mean
Croatian: Razlika u odnosu na glimepirid (srednja vrijednost prema metodi najmanjih kvadrata
English: EU/1/18/1265/022 (14 film-coated tablets) EU/1/18/1265/023 (28 film-coated tablets) EU/1/18/1265/024 (30x1 film-coated tablets) EU/1/18/1265/025 (56 film-coated tablets) EU/1/18/1265/026 (60 film-coated tablets) EU/1/18/1265/027 (168 film-coated tablets) EU/1/18/1265/028 (180 film-coated tablets) EU/1/18/1265/032 (196 (4 x 49) film-coated tablets)
Croatian: EU/1/18/1265/022 (14 filmom obloženih tableta) EU/1/18/1265/023 (28 filmom obloženih tableta) EU/1/18/1265/024 (30 x 1 filmom obložena tableta) EU/1/18/1265/025 (56 filmom obloženih tableta) EU/1/18/1265/026 (60 filmom obloženih tableta) EU/1/18/1265/027 (168 filmom obloženih tableta) EU/1/18/1265/028 (180 filmom obloženih tableta) EU/1/18/1265/032 (196 (4 x 49) filmom obloženih tableta)
English: Each tablet contains 2.5 mg ertugliflozin (as ertugliflozin L-pyroglutamic acid) and 850 mg of metformin hydrochloride.
Croatian: Jedna tableta sadrži 2,5 mg ertugliflozina (u obliku ertugliflozin-L-piroglutamatne kiseline) i 850 mg metforminklorida.
English: Segluromet 7.5 mg/850 mg film-coated tablets ertugliflozin/metformin hydrochloride
Croatian: Segluromet 7,5 mg/850 mg filmom obložene tablete ertugliflozin/metforminklorid
English: For patients inadequately controlled on metformin monotherapy or metformin in combination with other glucose-lowering medicinal products, including insulin The recommended starting dose of Segluromet should provide ertugliflozin 2.5 mg twice daily (5 mg daily dose) and the dose of metformin similar to the dose already being taken.
Croatian: Preporučena početna doza lijeka Segluromet treba osigurati primjenu 2,5 mg ertugliflozina dvaput na dan (dnevna doza od 5 mg) i dozu metformina sličnu dozi koju bolesnik već uzima.
English: EU/1/18/1265/008 (14 film-coated tablets) EU/1/18/1265/009 (28 film-coated tablets) EU/1/18/1265/010 (30x1 film-coated tablets) EU/1/18/1265/011 (56 film-coated tablets) EU/1/18/1265/012 (60 film-coated tablets) EU/1/18/1265/013 (168 film-coated tablets) EU/1/18/1265/014 (180 film-coated tablets) EU/1/18/1265/030 (196 (4 x 49) film-coated tablets)
Croatian: EU/1/18/1265/008 (14 filmom obloženih tableta) EU/1/18/1265/009 (28 filmom obloženih tableta) EU/1/18/1265/010 (30 x 1 filmom obložena tableta) EU/1/18/1265/011 (56 filmom obloženih tableta) EU/1/18/1265/012 (60 filmom obloženih tableta) EU/1/18/1265/013 (168 filmom obloženih tableta) EU/1/18/1265/014 (180 filmom obloženih tableta) EU/1/18/1265/030 (196 (4 x 49) filmom obloženih tableta)
English: OUTER CARTON FOR SEGLUROMET 7.5 mg/850 mg
Croatian: VANJSKA KUTIJA ZA SEGLUROMET 7,5 mg/850 mg
English: Baseline (mean) Change from baseline (LS mean Difference from Sitagliptin Ertugliflozin 5 mg Ertugliflozin 15 mg (LS mean
Croatian: Razlika u odnosu na sitagliptin ertugliflozin 5 mg ertugliflozin 15 mg (srednja vrijednost prema metodi najmanjih kvadrata 95% CI)
English: Segluromet 2.5 mg/1000 mg film-coated tablets ertugliflozin/metformin hydrochloride
Croatian: Segluromet 2,5 mg/1000 mg filmom obložene tablete ertugliflozin/metforminklorid
English: • dry mouth
Croatian: Primjena kroz usta
English: EU/1/18/1265/001 (14 film-coated tablets) EU/1/18/1265/002 (28 film-coated tablets) EU/1/18/1265/003 (30x1 film-coated tablets) EU/1/18/1265/004 (56 film-coated tablets) EU/1/18/1265/005 (60 film-coated tablets) EU/1/18/1265/006 (168 film-coated tablets) EU/1/18/1265/007 (180 film-coated tablets) EU/1/18/1265/029 (196 (4 x 49) film-coated tablets)
Croatian: EU/1/18/1265/001 (14 filmom obloženih tableta) EU/1/18/1265/002 (28 filmom obloženih tableta) EU/1/18/1265/003 (30 x 1 filmom obložena tableta) EU/1/18/1265/004 (56 filmom obloženih tableta) EU/1/18/1265/005 (60 filmom obloženih tableta) EU/1/18/1265/006 (168 filmom obloženih tableta) EU/1/18/1265/007 (180 filmom obloženih tableta) EU/1/18/1265/029 (196 (4 x 49) filmom obloženih tableta)
English: EU/1/18/1265/015 (14 film-coated tablets) EU/1/18/1265/016 (28 film-coated tablets) EU/1/18/1265/017 (30x1 film-coated tablets) EU/1/18/1265/018 (56 film-coated tablets) EU/1/18/1265/019 (60 film-coated tablets) EU/1/18/1265/020 (168 film-coated tablets) EU/1/18/1265/021 (180 film-coated tablets) EU/1/18/1265/031 (196 (4 x 49) film-coated tablets)
Croatian: EU/1/18/1265/015 (14 filmom obloženih tableta) EU/1/18/1265/016 (28 filmom obloženih tableta) EU/1/18/1265/017 (30 x 1 filmom obložena tableta) EU/1/18/1265/018 (56 filmom obloženih tableta) EU/1/18/1265/019 (60 filmom obloženih tableta) EU/1/18/1265/020 (168 filmom obloženih tableta) EU/1/18/1265/021 (180 filmom obloženih tableta) EU/1/18/1265/031 (196 (4 x 49) filmom obloženih tableta)
English: OUTER CARTON FOR SEGLUROMET 2.5 mg/1000 mg
Croatian: VANJSKA KUTIJA ZA SEGLUROMET 2,5 mg/1000 mg
English: OUTER CARTON FOR SEGLUROMET 7.5 mg/1000 mg
Croatian: VANJSKA KUTIJA ZA SEGLUROMET 7,5 mg/1000 mg
English: OUTER CARTON FOR SEGLUROMET 2.5 mg/850 mg
Croatian: VANJSKA KUTIJA ZA SEGLUROMET 2,5 mg/850 mg
English: Segluromet 2.5 mg/850 mg film-coated tablets
Croatian: Segluromet 2,5 mg/850 mg filmom obložene tablete ertugliflozin/metforminklorid
English: • feeling sick or being sick
Croatian: • mučnina ili povraćanje,
English: Each tablet contains 7.5 mg of ertugliflozin (as ertugliflozin L-pyroglutamic acid) and 850 mg of metformin hydrochloride.
Croatian: Jedna tableta sadrži 7,5 mg ertugliflozina (u obliku ertugliflozin-L-piroglutamatne kiseline) i 850 mg metforminklorida.
English: : + 359 2 819 3737 info-msdbg@merck.com
Croatian: Мерк Шарп и Доум България ЕООД Teл.: + 359 2 819 3737 info-msdbg@merck.com
English: Red, 19.1 x 10.6 mm oval, film-coated tablet debossed with “7.5/1000” on one side and plain on the other side.
Croatian: Segluromet 7,5 mg/1000 mg filmom obložene tablete Crvena, ovalna, filmom obložena tableta dimenzija 19,1 x 10,6 mm, s utisnutom oznakom „7.5/1000“ na jednoj strani i bez oznaka na drugoj strani.
English: • fainting
Croatian: • svrbež
English: • stomach ache
Croatian: • suha usta,
English: Pink, 19.1 x 10.6 mm oval, film-coated tablet debossed with “2.5/1000” on one side and plain on the other side.
Croatian: Segluromet 2,5 mg/1000 mg filmom obložene tablete Ružičasta, ovalna, filmom obložena tableta dimenzija 19,1 x 10,6 mm, s utisnutom oznakom „2.5/1000“ na jednoj strani i bez oznaka na drugoj strani.
English: Skin and subcutaneous tissue disorders Very rare
Croatian: Poremećaji bubrega i mokraćnog sustava često manje često pojačano mokrenje dizurija
English: increased à,1
Croatian: , povišene vrijednosti ureje u krvi à,1
English: Tel: + 386 1 5204201 msd_slovenia@merck.com
Croatian: Merck Sharp & Dohme, inovativna zdravila d.o.o. Tel: + 386 1 5204201 msd_slovenia@merck.com
English: Beige, 18 x 10 mm oval, film-coated tablet debossed with “2.5/850” on one side and plain on the other side.
Croatian: Segluromet 2,5 mg/850 mg filmom obložene tablete Bež, ovalna, filmom obložena tableta dimenzija 18 x 10 mm, s utisnutom oznakom „2.5/850“ na jednoj strani i bez oznaka na drugoj strani.